Perspective is advancing multiple clinical programs across a range of tumors, and is using its proprietary platform to generate a robust pipeline novel pre-IND assets.
| PROGRAM (TARGET) |
TARGET DISEASE | CANDIDATE EVALUATION | HUMAN CLINICAL IMAGING | PHASE 1/2 | REGISTRATION ENABLING STUDY | STATUS |
|---|---|---|---|---|---|---|
| VMT-α-NET (SSTR2) |
Neuroendocrine Tumors Other SSTR2+ Tumors |
|
Phase 1/2a updates
throughout 2026
Initiate dosing in 2026 |
|||
| VMT01 (MC1R) |
Melanoma (Imaging & Therapy) Melanoma (Imaging & Therapy) |
|
Initial Phase 1/2a data late 2026
Initial Phase 1/2a data late 2026 |
|||
| PSV359 (FAP-α) |
Solid Tumors | Initial Phase 1/2a data late 2026 | ||||
| PSV594 (CCK2R) |
Solid Tumors | Initiate dosing | ||||
| Multiple (Undisclosed) |
Undisclosed | First in human images | ||||